Europe launch readiness Triojection is CE marked and poised for commercial rollout in Europe, presenting a near-term opportunity for distributors and clinics in EU markets as a first expansion channel.

Non-surgical niche Product targets herniated discs with a non-surgical ozone injection approach, positioning Minimus Spine to engage spine specialists and interventional pain clinics seeking nonoperative options for patients and potential discectomy avoidance.

Clinical study leverage Active multi-center randomized European study comparing Triojection to surgical discectomy can be leveraged to support prescription and purchasing decisions, co-marketing with research institutions, and clinician education efforts.

Regulatory and access gaps Limited U.S. availability and European regulatory proximity create a need for regional partnerships, distribution agreements, and regulatory planning to accelerate market access and revenue growth.

Resource-constrained scale Small team size implies potential emphasis on strategic partnerships, OEM/white-label opportunities, and targeted outreach to top spine centers to maximize impact with lean operations.